| Literature DB >> 28018476 |
Rym Mensi1, Amal Messaoud1, Ahmed Mhallah2, Islem Azizi1, Walid Haj Salah2, Wahiba Douki1, Mohamed Fadhel Najjar3, Lotfi Gaha2.
Abstract
BACKGROUND: There have been many studies on psychiatric disorders, but very little is known about the biology of suicide with schizophrenia. In the present study, we are looking for a possible connection between altered lipid profile and suicidal behavior in schizophrenic Tunisian patients.Entities:
Keywords: Cholesterol; Lipids; Schizophrenia; Suicide
Year: 2016 PMID: 28018476 PMCID: PMC5162100 DOI: 10.1186/s12991-016-0123-1
Source DB: PubMed Journal: Ann Gen Psychiatry ISSN: 1744-859X Impact factor: 3.455
Demographic characteristics of different groups of study population
| Demographic characteristics | ±SD/freq. (%) |
| |
|---|---|---|---|
| Schizophrenia group ( | Controls group ( | ||
| Gender | |||
| Male | 91 (72.2%) | 94 (71.8%) | 0.934 |
| Female | 35 (27.8%) | 37 (28.2%) | |
| Sex ratio | 2.6 | 2.54 | |
| Age (year) | 43.44 ± 10.60 | 40.81 ± 14.60 | 0.101 |
| BMI (kg/m2) | 26.25 ± 5.86 | 24.86 ± 3.82 |
|
| Smoking status | |||
| Smoking | 73 (57.9%) | 54 (41.2%) | 0.713 |
| No-smoking | 51 (40.5%) | 77 (58.8%) | |
| Weaned | 2 (1.6%) | 0 (0%) | |
| Alcoholic status | |||
| Consumer | 24 (19%) | 14 (10.7%) | 0.056 |
| No-consumer | 102 (81%) | 117 (89.3%) | |
Clinical characteristics of schizophrenic patients with and without suicide attempts
| Patients without SA ( | Patients with SA ( |
| |
|---|---|---|---|
| Psychometric evaluation | |||
| PANSS general | 35.25 ± 14.97 | 41.71 ± 15.86 |
|
| PANSS positive | 14.70 ± 6.83 | 19.80 ± 8.88 |
|
| PANSS negative | 17.52 ± 8.93 | 20.76 ± 9.02 |
|
| CGI severity | 3.01 ± 1.61 | 3.31 ± 1.46 |
|
| CGI overall improvement | 2.32 ± 1.20 | 2.22 ± 0.91 | 0.292 |
| CGI therapeutic index | 4.94 ± 3.49 | 5.20 ± 3.34 | 0.590 |
| EGF | 61.42 ± 18.21 | 53.27 ± 17.44 | 0.678 |
| BPRS | 53.49 ± 23.53 | 69.24 ± 25.24 |
|
| Calgary | 6.56 ± 10.11 | 8.31 ± 6.21 | 0.262 |
| Type of schizophrenia | |||
| Undifferentiated | 35 (47.88%) | 17 (30.90%) | 0.113 |
| Paranoid | 23 (32.39%) | 25 (45.44%) | |
| Disorganized | 13 (18.30%) | 13 (23.64%) | |
| Neuroleptics | |||
| Typical | 59 (83.1%) | 47 (85.5%) | 0.952 |
| Typical and atypical | 12 (16.9%) | 8 (13.5%) | |
| Doses of chlorpromazine | 990.07 ± 617.703 | 963.18 ± 652.663 | 0.814 |
| Age at onset (year) | 25.99 ± 8.39 | 25.26 ± 8.98 | 0.643 |
Fig. 1Plasma concentrations of lipid parameters in schizophrenic patients and controls. *ANOVA: p adjusted for BMI
Comparison of lipid profile in schizophrenic patients depending on the seniority of suicide attempt
| Blood levels | Recent suicide attempters | Lifetime suicide attempters | Never-suicide attempters |
| [ | [ | [ |
|---|---|---|---|---|---|---|---|
| TC (mmol/L) | 3.19 ± 1.00 | 4.02 ± 0.96 | 4.39 ± 0.98 |
|
|
| 0.063 |
| HDL-C (mmol/L) | 1.66 ± 0.94 | 1.64 ± 1.04 | 1.64 ± 0.93 | 0.995 | 0.935 | 0.920 | 0.994 |
| LDL-C (mmol/L) | 1.04 ± 0.36 | 1.04 ± 0.27 | 1.04 ± 0.27 | 0.921 | 0.947 | 0.848 | 0.691 |
| TG (mmol/L) | 2.60 ± 0.50 | 2.62 ± 1.11 | 2.62 ± 1.12 | 0.847 | 0.934 | 0.746 | 0.597 |
Variations of lipid profile in schizophrenic patients according to the treatment
| Neuroleptics |
| |||
|---|---|---|---|---|
| Typical [ | Atypical [ | Typical and atypical [ | ||
| TC (mmol/L) | 4.16 ± 1.07 | 4.05 ± 0.25 | 4.05 ± 1.01 | 0.933 |
| TG (mmol/L) | 1.70 ± 1.41 | 1.41 ± 0.87 | 1.26 ± 0.64 | 0.210 |
| HDL-C (mmol/L) | 1.03 ± 0.28 | 1.21 ± 0.36 | 1.17 ± 0.48 | 0.145 |
| LDL-C (mmol/L) | 2.57 ± 0.98 | 2.25 ± 0.50 | 2.56 ± 0.72 | 0.797 |
Correlation of lipid profile in schizophrenic patients according to the psychometric evaluation for patients with recent suicide attempt
| TC (mmol/L) | TG (mmol/L) | HDL-c (mmol/L) | LDL-c (mmol/L) | |
|---|---|---|---|---|
| PANSS general | ||||
| | −0.050 | −0.19 | −1.17 | 0.04 |
| | 0.575 | 0.830 | 0.191 | 0.967 |
| PANSS + | ||||
| | −0.11 | −0.014 | −0.093 | 0.076 |
| | 0.901 | 0.875 | 0.301 | 0.398 |
| PANSS − | ||||
| | 0.073 | 0.018 | −0.020 | −0.006 |
| | 0.418 | 0.844 | 0.824 | 0.946 |
| CGI severity | ||||
| | −0.036 | 0.029 | −0.142 | 0.039 |
| | 0.689 | 0.749 | 0.114 | 0.664 |
| CGI improving patients under treatment | ||||
| | −1.06 | 0.051 | −0.075 | −0.006 |
| | 0.237 | 0.569 | 0.404 | 0.945 |
| CGI therapeutic index | ||||
| | −0.057 | −0.075 | −0.090 | −0.06 |
| | 0.523 | 0.406 | 0.315 | 0.502 |
| EGF | ||||
| | − | −0.058 | −0.0514 | −0.119 |
| |
| 0.515 | 0.550 | 0.184 |
| Calgary | ||||
| |
| −0.046 | 0.132 | 0.150 |
| |
| 0.609 | 0.139 | 0.093 |
Fig. 2Roc curve assessing the different threshold values (TC, TG, HDL-c, and LDL-c) for patients with schizophrenia based on SA history
Fig. 3Roc curve assessing the different threshold values (TC, TG, HDL-c, and LDL-c) for patients with schizophrenia based on seniority of SA history
Total cholesterol, triglycerides, HDL-c, and LDL-c levels in schizophrenic patients with and without suicide attempters
| Schizophrenia | OR | Confidence interval 95% |
| ||
|---|---|---|---|---|---|
| Without SA | With SA | ||||
| TC (mmol/L) | |||||
| ≤3.51 | 12 (16.9%) | 21 (38.2%) |
| 1.330–6.932 |
|
| >3.51 | 59 (83.1%) | 34 (61.8%) | |||
| TG (mmol/L) | |||||
| ≤1.61 | 41 (57.7%) | 34 (61.8%) | 0.844 | 0.411–1.733 | 0.785 |
| >1.61 | 30 (42.3%) | 21 (38.2%) | |||
| HDL-C (mmol/L) | |||||
| ≤1.10 | 39 (54.9%) | 36 (65.5%) | 0.643 | 0.311–1.330 | 0. 563 |
| >1.10 | 32 (45.1%) | 19 (34.5%) | |||
| LDL-C (mmol/L) | |||||
| ≤2.5 | 39 (54.9%) | 24 (43.6%) | 1.574 | 0.775–3.198 | 0.480 |
| >2.5 | 32 (45.1%) | 31 (56.4%) | |||
Total cholesterol, triglycerides, HDL-c, and LDL-c levels in schizophrenic patients with schizophrenia based on seniority of SA
| Schizophrenia | OR | Confidence interval 95% |
| ||
|---|---|---|---|---|---|
| Lifetime SA | Recent SA | ||||
| TC (mmol/L) | |||||
| ≤3.76 | 26 (36.6%) | 12 (80%) |
| 1.787–26.816 |
|
| >3.76 | 45 (63.4%) | 3 (20%) | |||
| TG (mmol/L) | |||||
| ≤1.71 | 46 (64.8%) | 9 (60%) | 1.227 | 0.392–3.843 | 0.964 |
| >1.71 | 25 (35.2%) | 6 (40%) | |||
| HDL-c (mmol/L) | |||||
| ≤1.13 | 44 (62%) | 11 (73.3%) | 0.593 | 0.171–2.049 | 0.641 |
| >1.13 | 27 (38%) | 4 (26.7%) | |||
| LDL-c (mmol/L) | |||||
| ≤2.50 | 39 (54.9%) | 6 (40%) | 1.828 | 0.588–5.681 | 0.539 |
| >2.50 | 32 (45.1%) | 9 (60%) | |||